Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sub-anesthetic ketamine infusions may benefit a range of psychiatric conditions, including alcohol and cocaine use disorders. Currently, there are no effective pharmacological treatments for cannabis use disorder. OBJECTIVES: The objective of this uncontrolled proof of concept trial was to test the feasibility, tolerability, and potential therapeutic effects of integrating ketamine infusions with a behavioral platform of motivational enhancement therapy and mindfulness-based relapse prevention in treating cannabis use disorder (CUD). METHODS: Eight cannabis-dependent individuals (four female, four male) receiving motivational enhancement therapy and mindfulness-based relapse prevention behavioral treatments completed this single-blind outpatient 6-week study. Participants received either one or two infusions of ketamine (0.71 mg/kg [infusion 1]; 1.41 mg/kg [infusion 2] for non-responders) during the study. Participants self-reported cannabis use (Timeline Follow-Back) and underwent an assessment of confidence in abstaining from using cannabis (Drug-Taking Confidence Questionnaire) at predetermined time points throughout the study. RESULTS: Ketamine infusions were well-tolerated and there were no adverse events. Frequency of cannabis use decreased significantly from baseline (B = 5.1, s.e = 0.7) to the week following the first infusion (B = 0.8, s.e = 0.412), and remained reduced at the end of the study (B = 0.5, s.e = 0.3). Participants' confidence in their ability to abstain from cannabis in potentially triggering situations increased significantly from baseline to the end of study. CONCLUSIONS: These findings suggest that combining ketamine with behavioral therapy is feasible,tolerable, and potentially helpful, in treating cannabis-dependent individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a proof-of-concept study (n = 8), ketamine significantly decreased self-reported cannabis use in combination with motivational enhancement therapy and mindfulness-based relapse prevention [146]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [146]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513 · cited 1×
“Participants underwent comprehensive psychiatric and medical assessments, including the Mini-International Neuropsychiatric Interview for the DSM-IV (MINI) (20).”
Method(1993) · Cited by 1,279
Mindfulness-Based Relapse Prevention for Substance Use Disorders: A Pilot Efficacy Trial
Bowen, S., Chawla, N., Collins, S. E., Witkiewitz, K., Hsu, S., Grow, J., Clifasefi, S., Garner, M., Douglass, A., Larimer, M. E., et al. (2009) · Substance Abuse · doi:10.1080/08897070903250084 · Cited by 715
Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use
Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014) · Psychology of Addictive Behaviors · doi:10.1037/a0030992 · Cited by 699
Budney, A. J., Higgins, S. T., Radonovich, K. J., & Novy, P. L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.6.1051 · Cited by 318
Brief treatments for cannabis dependence: Findings from a randomized multisite trial
Babor, T. F., & The Marijuana Treatment Project Research Group (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.3.455 · Cited by 313
Budney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.4.2.307 · Cited by 290
Brewer, J. A., Sinha, R., Chen, J. A., Michalsen, R. N., Babuscio, T. A., Nich, C., Grier, A., Bergquist, K. L., Reis, D. L., Potenza, M. N., et al. (2009) · Substance Abuse · doi:10.1080/08897070903250241 · Cited by 286
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232 · cited 1×
“Similarly, an earlier double-blind study examining the effects of weekly therapy sessions (utilizing a component of MET) in combination with either dronabinol or placebo over 12 weeks (28) demonstrated a small proportion of abstinence: 21.”
BackgroundSelf-citationTreatment of Cannabis Use Disorder: Current Science and Future Outlook
Sherman, B. J., & McRae‐Clark, A. L. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1747 · Cited by 208
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186 · cited 4×
“Previous clinical trials with alcohol-dependent (18) and cocaine-dependent (19) populations have found that ketamine might be helpful at facilitating MET and MBRP, respectively.”
BackgroundResultSelf-citationSingle Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399860 · Cited by 183
Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070684 · Cited by 183
Self-citationDakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143 · cited 2×
“As in previous studies (14,15,18,19), participants responded well to the ketamine infusions, suggesting that when administered to prepared and appropriate participants in a carefully monitored framework, ketamine is associated with minimal behavioral and cardiovascular toxicity.”
BackgroundResultSelf-citationTreatment of Cannabis Use Disorders: A Review of the Literature
Nordstrom, B. R., & Levin, F. R. (2007) · The American Journal on Addictions · doi:10.1080/10550490701525665 · Cited by 120
Self-citationPharmacotherapy for Cannabis Dependence: How Close Are We?
Vandrey, R., & Haney, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00001 · Cited by 108
Dakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.39 · Cited by 105
Self-citationRelapse in outpatient treatment for marijuana dependence
Moore, B. A., & Budney, A. J. (2003) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(03)00083-7 · Cited by 98
Carroll, K. M., Nich, C., LaPaglia, D. M., Peters, E. N., Easton, C. J., & Petry, N. M. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03877.x · Cited by 91
A placebo-controlled trial of buspirone for the treatment of marijuana dependence
McRae-Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., Wahlquist, A. E., Simpson, S. A., & Brady, K. T. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.06.022 · Cited by 87
Litt, M. D., Kadden, R. M., & Petry, N. M. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.08.011 · Cited by 71
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 40
Dakwar, E., & LEVIN, F. R. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12036.x · Cited by 16
Self-citationGuanfacine extended-release for cannabis use disorder: A pilot feasibility trial
Dakwar, E., Mahony, A., Choi, C. J., Pavlicova, M., Brooks, D., Mariani, J. J., & Levin, F. R. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1620259 · Cited by 5 · cited 1×
“In an eight-week outpatient open-label trial investigating guanfacine titration as a potential treatment (27), 13.”
BackgroundSelf-citation
Research works printed but not linked: 4
- Substance Abuse and Mental Health Services Administration, 2019, Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health (HHS Publication No. PEP19-5068, NSDUH series H-54)
- 10.1037/0022-006X.74.2.307 · DOI · Paper page
- Carlson EB, 1993, Dissociation, 6, 16
- Smedslund G, 2011, Cochrane Database Syst Rev, 5, CD008063
Cited by
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J. D., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) · Journal of Pain Research · doi:10.2147/jpr.s360733 · Cited by 151
“46 This is compounded by the significant time and financial costs to patients involved in the uptake of KAP.”
InfluentialKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“In a proof-of-concept study ( n = 8), ketamine signi fi - cantly decreased self-reported cannabis use in combination with motivational enhancement therapy and mindfulness-based relapse prevention [146].”
BackgroundKetamine and psychotherapy for the treatment of psychiatric disorders: Systematic review
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023) · BJPsych Open · doi:10.1192/bjo.2023.53 · Cited by 69
Metadata
- Authors
- Azhari, N., Hu, H., O’Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Dakwar, Elias
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2020-11-11
- Volume
- 47
- Issue
- 1
- Pages
- 92-97
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- OpenAlex
- W3098995086
- Cited by
- 48
- References
- 26
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 8 · 2023: 7 · 2022: 8 · 2021: 2
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Funders
- National Institute of Drug Abuse (DA029647)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- ketamine, cannabis use disorder, motivational enhancement therapy, mindfulness-based relapse prevention, cannabis use reduction
- MeSH terms
- Proof of Concept Study, Adult, Behavior Therapy, Marijuana Abuse, Female, Humans, Ketamine, Male, Middle Aged, Single-Blind Method, Treatment Outcome, Excitatory Amino Acid Antagonists, Young Adult, Mindfulness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.